Cargando…
Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction
SIMPLE SUMMARY: Cancer is a complex, heterogeneous collection of diseases with hundred of different subtypes. Genomic aberrations that are primarily thought to be the root causes of different cancers have been clinically used as evidence for both the diagnosis and also matching individual patients t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688044/ https://www.ncbi.nlm.nih.gov/pubmed/36428696 http://dx.doi.org/10.3390/cancers14225604 |
_version_ | 1784836167162658816 |
---|---|
author | Baranovskii, Artem Gündüz, Irem B. Franke, Vedran Uyar, Bora Akalin, Altuna |
author_facet | Baranovskii, Artem Gündüz, Irem B. Franke, Vedran Uyar, Bora Akalin, Altuna |
author_sort | Baranovskii, Artem |
collection | PubMed |
description | SIMPLE SUMMARY: Cancer is a complex, heterogeneous collection of diseases with hundred of different subtypes. Genomic aberrations that are primarily thought to be the root causes of different cancers have been clinically used as evidence for both the diagnosis and also matching individual patients to proper treatment options. However, the complexity of cancer manifests itself differently in each patient when inspected at the molecular level. Even patients with the same cancer type rarely have identical root causes for the same disease. Without an extensive molecular profile of a patient, it has been challenging to match the patients to the best treatment options. To remedy this, comprehensive genomic profiling panels have been developed to monitor hundreds of genes for a given patient, which has helped broaden the treatment options for patients. However, genomic aberrations detected in such panels still do not reflect the full complexity of how a tumour responds to cancer drugs. In this study, we demonstrate that using an additional layer of molecular information (called the transcriptome) on top of genomic aberrations that can be detected with cancer gene panels can provide significant improvements in predicting the cancer drug response in pre-clinical cancer models. Thus, this study serves as a push towards incorporating the transcriptome measurements more routinely in (pre-)clinical practice. ABSTRACT: Comprehensive genomic profiling using cancer gene panels has been shown to improve treatment options for a variety of cancer types. However, genomic aberrations detected via such gene panels do not necessarily serve as strong predictors of drug sensitivity. In this study, using pharmacogenomics datasets of cell lines, patient-derived xenografts, and ex vivo treated fresh tumor specimens, we demonstrate that utilizing the transcriptome on top of gene panel features substantially improves drug response prediction performance in cancer. |
format | Online Article Text |
id | pubmed-9688044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96880442022-11-25 Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction Baranovskii, Artem Gündüz, Irem B. Franke, Vedran Uyar, Bora Akalin, Altuna Cancers (Basel) Communication SIMPLE SUMMARY: Cancer is a complex, heterogeneous collection of diseases with hundred of different subtypes. Genomic aberrations that are primarily thought to be the root causes of different cancers have been clinically used as evidence for both the diagnosis and also matching individual patients to proper treatment options. However, the complexity of cancer manifests itself differently in each patient when inspected at the molecular level. Even patients with the same cancer type rarely have identical root causes for the same disease. Without an extensive molecular profile of a patient, it has been challenging to match the patients to the best treatment options. To remedy this, comprehensive genomic profiling panels have been developed to monitor hundreds of genes for a given patient, which has helped broaden the treatment options for patients. However, genomic aberrations detected in such panels still do not reflect the full complexity of how a tumour responds to cancer drugs. In this study, we demonstrate that using an additional layer of molecular information (called the transcriptome) on top of genomic aberrations that can be detected with cancer gene panels can provide significant improvements in predicting the cancer drug response in pre-clinical cancer models. Thus, this study serves as a push towards incorporating the transcriptome measurements more routinely in (pre-)clinical practice. ABSTRACT: Comprehensive genomic profiling using cancer gene panels has been shown to improve treatment options for a variety of cancer types. However, genomic aberrations detected via such gene panels do not necessarily serve as strong predictors of drug sensitivity. In this study, using pharmacogenomics datasets of cell lines, patient-derived xenografts, and ex vivo treated fresh tumor specimens, we demonstrate that utilizing the transcriptome on top of gene panel features substantially improves drug response prediction performance in cancer. MDPI 2022-11-15 /pmc/articles/PMC9688044/ /pubmed/36428696 http://dx.doi.org/10.3390/cancers14225604 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Baranovskii, Artem Gündüz, Irem B. Franke, Vedran Uyar, Bora Akalin, Altuna Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction |
title | Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction |
title_full | Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction |
title_fullStr | Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction |
title_full_unstemmed | Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction |
title_short | Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction |
title_sort | multi-omics alleviates the limitations of panel sequencing for cancer drug response prediction |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688044/ https://www.ncbi.nlm.nih.gov/pubmed/36428696 http://dx.doi.org/10.3390/cancers14225604 |
work_keys_str_mv | AT baranovskiiartem multiomicsalleviatesthelimitationsofpanelsequencingforcancerdrugresponseprediction AT gunduziremb multiomicsalleviatesthelimitationsofpanelsequencingforcancerdrugresponseprediction AT frankevedran multiomicsalleviatesthelimitationsofpanelsequencingforcancerdrugresponseprediction AT uyarbora multiomicsalleviatesthelimitationsofpanelsequencingforcancerdrugresponseprediction AT akalinaltuna multiomicsalleviatesthelimitationsofpanelsequencingforcancerdrugresponseprediction |